AVVie

AVVie GmbH has developed a unique technology for repairing cardiac mitral valve prolapse called the Mitral Butterfly implant. With more than 50% of the affected patient population currently untreated, the market potential for this innovative solution is significant.  The Company operates under a robust business model that leverages its unique technology to generate revenue and establish the Mitral Butterfly implant as the standard of care for patients with mitral valve regurgitation. The Company is led by an experienced team whose objective is to drive the commercial success of the Mitral Butterfly implant.